Emmes Group, a leading global contract research organization (CRO), has entered into a multi-year strategic partnership with Miimansa AI. This collaboration focuses on integrating Miimansa’s advanced Clinical Entity Modeling tools, leveraging Large Language Models (LLM) and generative AI techniques to revolutionize clinical research at Emmes.
1. Partnership Overview
- Emmes Group and Miimansa AI form a strategic partnership.
- Acquisition of Miimansa’s Clinical Entity Modeling tools to enhance clinical research.
2. AI Integration and Technology
- Emmes is developing its Veridix AI technology platform using Miimansa’s tools.
- Focus on automating text processing for clinical research tasks such as protocol creation and medical report writing.
3. Benefits and Goals
- Aims to process large volumes of clinical data rapidly and accurately.
- Reduces time and cost of manual data processing and analysis.
- Enhances text-to-text interfaces for more efficient clinical research operations.
4. Statements from Leadership
- Sastry Chilukuri, CEO of Emmes Group, highlights the potential of the partnership to accelerate clinical trials.
- Dr. Vibhu Agarwal, Founder and CEO of Miimansa AI, emphasizes the opportunity to apply advanced AI techniques in real-world settings.
5. Future Implications
- The partnership aims to make clinical research faster, more accessible, and effective.
- Expected to improve the development and application of Emmes’s generative AI platform, Concord.
The strategic partnership between Emmes Group and Miimansa AI marks a significant advancement in clinical research technology. By integrating cutting-edge AI and clinical entity modeling tools, the collaboration is set to accelerate clinical trials, enhance data processing, and ultimately contribute to safer and more effective treatments.
